RenovoRx, Inc. (RNXT)
1.28
-0.05
(-3.76%)
USD |
NASDAQ |
Oct 09, 16:00
1.32
+0.04
(+3.12%)
After-Hours: 20:00
RenovoRx Free Cash Flow : -11.94M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.94M |
| March 31, 2026 | -11.30M |
| December 31, 2025 | -10.98M |
| September 30, 2025 | -10.40M |
| June 30, 2025 | -10.32M |
| March 31, 2025 | -10.32M |
| December 31, 2024 | -9.137M |
| September 30, 2024 | -8.748M |
| June 30, 2024 | -9.282M |
| March 31, 2024 | -9.756M |
| Date | Value |
|---|---|
| December 31, 2023 | -10.26M |
| September 30, 2023 | -9.886M |
| June 30, 2023 | -9.83M |
| March 31, 2023 | -9.42M |
| December 31, 2022 | -8.811M |
| September 30, 2022 | -9.688M |
| June 30, 2022 | -8.135M |
| March 31, 2022 | -7.036M |
| December 31, 2021 | -5.931M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Enanta Pharmaceuticals, Inc. | -36.94M |
| Travere Therapeutics, Inc. | 15.40M |
| REGENXBIO, Inc. | -249.67M |
| Krystal Biotech, Inc. | 257.78M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.867M |
| Cash from Investing (Quarterly) | -0.071M |
| Cash from Financing (Quarterly) | 0.055M |
| Free Cash Flow Per Share (Quarterly) | -0.0621 |
| Free Cash Flow to Equity (Quarterly) | -3.142M |
| Free Cash Flow to Firm (Quarterly) | -2.938M |
| Free Cash Flow Yield | -23.52% |